Samsung Bioepis has launched Ustekinumab BS 45 mg Syringe for SC Injection NIPRO, a biosimilar referencing Stelara (ustekinumab), marking its first product launch in Japan under partnership with Nipro Corporation. The launch follows the Official Gazette announcement on May 19 regarding the product’s listing under the National Health Insurance (NHI) Drug Price Standard.

Jinhan Chung, Vice President and Head of Commercial Strategy for International Markets, Samsung Bioepis, said, "We are thrilled to announce the launch of our first biosimilar product in Japan in partnership with NIPRO. Together with our partner NIPRO, we look forward to supporting patients living with autoimmune diseases and contributing to the sustainability of Japan's healthcare system by providing quality-assured, safe and effective biosimilar options.”

Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted marketing authorisation to Ustekinumab BS 45 mg Syringe for SC Injection?NIPRO? for the treatment of plaque psoriasis, and psoriatic arthritis in December 2025.

The company announced a strategic partnership with NIPRO for the development and commercialisation of multiple biosimilar candidates in Japan, including ustekinumab, in June 2025.

Its ustekinumab biosimilar is available under different brand names across the European Union (EU), Korea, the United Kingdom (UK), and the United States (US).